PROCEDURAL STEPS TAKEN AFTER AUTHORISATION 
For procedures finalised after 1 September 2004 please refer to module 8B 
Scope 
Application 
number 
Type of 
modification1 
Notification/ 
Opinion 
issued on2 
Commission 
Decision 
Issued/amended 
on 
_ 
Change of storage container of the active 
substance 
Additional pack size 
10 x 3 ml Penfill 
Additional pack size 
10 x 3 ml Novolet 
Additional pack size 
5 x 10 ml NovoRapid 
Update of SPC and PL with regard to post 
prandial administration 
Additional presentation:  
FlexPen 
Update of SPC and PL with regard to 
“early hypoglycaemia in general” and 
“safe use in children” 
Update of SPC and PL with regard to 
continuous subcutaneous insulin infusion 
for Novorapid vials 
Change in the test procedure of the active 
substance and medicinal product 
Additional facility for purification of 
Insulin Aspart 
Change in the batch size of the finished 
product 
Change for the deletion of the bio identity 
test 
Update of the SPC and PL regarding the 
occurrence of fewer nocturnal 
hypoglycaemic episodes 
Minor change of the manufacturing 
process of the active substance 
Additional pack size 
1x3ml FlexPen 
I/01 
II/02 
II/03 
II/04 
II/05 
II/06 
II/07 
II/08 
I/09 
II/10 
I/11 
II/12 
II/13 
I/14 
I/15 
New route of administration (intravenous) 
X/16 
Change in batch size for Novorapid vials 
Change in batch size 
New route of administration (intravenous) 
for all presentations 
I/17 
I/18 
X/19 
 I/II 
18.11.99 
 II 
 II 
 II 
II 
II 
 II 
 II 
I 
II 
I/II 
II 
 II 
21.10.99 
08.02.00 
21.10.99 
08.02.00 
21.10.99 
08.02.00 
18.11.99 
13.04.00 
28.08.00 
15.01.01 
14.12.00 
23.04.01 
26.04.01 
13.07.01 
01.03.01 
20.09.01 
13.12.01 
21.02.02 
_ 
_ 
_ 
_ 
21.03.02 
15.07.02 
 I/II 
21.02.02 
16.01.02 
18.12.02  
30.05.02 
27.06.02 
 I 
 X 
 I/II 
 I/II 
 X 
18.12.02 
04.06.03 
_ 
_ 
04.06.03 
_ 
_ 
1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended, and for variations after  
1 October 2003 in accordance with Commission Regulation (EC) No 1085/2003: I refers to a minor variation (Type I 
variation); II refers to a major variation (Type II variation); I/II refers to a minor variation following the procedure set out in 
Article 6, 7 and 8 of the Regulation; X refers to an Annex II application. 
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of 7 
November 1996.  
N refers to a notification in accordance with Article 61(3) of Council Directive 2001/83/EC. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification date. The 
Commission Decision will be amended accordingly. 
                                                                                                        1/2                                                                        EMEA 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                      
 
Additional presentation:  
InnoLet 
Update of the SPC and PL with regard to 
continuous subcutaneous insulin infusion 
for all presentations 
Change in or addition of manufacturing 
site(s) for part or all of the manufacturing 
process 
Change in or addition of manufacturing 
site(s) for part or all of the manufacturing 
process 
Minor changes in manufacture of the 
medicinal product 
Qualitative change to the active substance 
Update of sections 4.4 and 4.8 of SPC and 
PL 
General update of  SPC and PL  
Update of or change to the pharmaceutical 
documentation 
Update of or change to the pharmaceutical 
documentation 
II/21 
II/22 
I/24 
I/25 
I/26 
X/27 
II/28 
II/29 
II/30 
II/31 
II 
II 
I 
I 
I 
X 
II 
II 
II 
II 
18.12.02 
04.06.03 
23.01.03 
06.06.03 
20.06.03 
16.07.03 
25.09.03 
03.06.04 
26.02.04 
26.02.04 
24.03.04 
22.04.04 
- 
- 
- 
24.08.04 
07.04.04 
07.04.04 
- 
- 
                                                                                                        2/2                                                                        EMEA 2004 
 
 
 
 
 
 
 
 
 
 
